Donald Trump’s call to deregulate psychedelics boosts drugmakers’ shares
Stock in UK-based Compass Pathways jumps to highest level in two years following president’s executive order
Related reading
Marijuana stocks tumble as Trump reclassifies drug but stops short of…
US president’s order would categorise cannabis as less dangerous and remove it from grouping with heroin and LSD
Europe races to placate pharma as Donald Trump turns up the pressure
Tariff deals with the US have bought time but investment momentum is elsewhere
US set to speed up approval for some generic drugs in blow to Big Pharma
Move is latest broadside by Trump administration against pharmaceuticals industry that fought to derail changes
Permira seeks $4bn for sale of contract drugmaker Cambrex
Trump’s threat of pharmaceutical tariffs has boosted investor interest in US drugmakers
Powerful new cannabis outstrips dangers of ‘Woodstock pot’
EU agency warns potent forms of recreational drug flooding Europe put users at risk of severe damage to mental health
US readies new pharmaceutical tariffs
Levies of 100% on certain medicines would implement threats Trump made last year